GlassScriptPhysician profile
Wilson Sze
NPI 1043606163
$8,894.26
in general payments reported to CMS, 2019-2025
52 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $315 · 2021: $1,291 · 2022: $1,385 · 2023: $2,133 · 2024: $2,080 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,853 · Education: $50.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,852.85 |
| Education | $50.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $776.13 | 2022-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $733.26 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Novo Nordisk INC | $662.35 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $530.44 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.30 | 2020-2024 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $454.25 | 2020-2024 | Verquvo, Steglatro, Steglujan |
| Abbott Laboratories | $430.69 | 2022-2025 | Freestyle Libre 3, Ensite, Eterna |
| Xeris Pharmaceuticals, INC. | $359.22 | 2021-2025 | Gvoke Hypopen |
| Amgen INC. | $353.07 | 2022-2025 | Evenity, Prolia, Repatha |
| Tandem Diabetes Care, INC. | $247.66 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cvrx, INC. | $247.22 | 2022-2024 | Barostim Neo System |
| Abbvie INC. | $241.60 | 2021-2025 | |
| Radius Health, INC. | $234.73 | 2024-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $234.64 | 2022-2025 | |
| Amphastar Pharmaceuticals, INC. | $227.32 | 2024-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Sze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.